anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Virtual meetings are widespread in organizations despite being perceived as fatiguing; a phenomenon also known as Zoom fatigue. Research suggests that Zoom fatigue is stronger when the camera is on, potentially influencing individuals to conform to majority opinions during professional online meetings. Two preregistered studies were conducted to explore the relationships between camera use, Zoom fatigue, social presence, and conformity. Study 1 involved 287 participants describing a professional online meeting in terms of the content discussed as well as the study variables. Study 2 involved 64 participants in an experimentally manipulated online meeting (camera on vs. off), focusing on a personnel selection task. We measured how many times participants changed their answers to match the majority and how this was related to Zoom fatigue and self-reported conformity. Results from both studies indicated that camera use was not related to either conformity or Zoom fatigue. Despite not finding the presumed mediation effect, the studies showed a clear link between fatigue and conformity. The results explain the emergence of conformity in online meetings and provide practical information for the design of video conferences.
OBJECTIVE: Occupational voice users (OVU) are at risk for developing voice disorders (VD). Otolaryngologists need to advocate for workplace accommodations for these patients. The objective of this study was to assess the literature on VDs in the workplace and to describe how results may guide the Otolaryngologist.
DATA SOURCES: EBSCO, PubMed, Google Scholar, UBC libraries, and SpringerLink databases.
REVIEW METHODS: The Preferred Reporting Items for Systematic Reviews and Meta-analysis extension for Scoping Reviews protocol was used to conduct a scoping review from inception to December 30, 2019. Oxford Levels of Evidence were used to assess the quality of included studies. Common themes and types of accommodations and barriers were explored. This study was registered with the Open Science Framework Open Source for Collaboration in Scientific Research (10.17605/OSF.IO/RYDVN).
RESULTS: One hundred and ninety-three abstracts were screened; 32 studies met inclusion criteria. Oxford Levels of Evidence ranged from 3 to 5. Eight overarching themes were identified: prevalence of VDs among OVUs; identifying risk factors for VDs; raising awareness of VDs medico-legally, politically; the education and treatment of VDs, the importance of diagnosing VDs; measuring the impact of VDs on work productivity; identifying perceived barriers to integration into the workplace; and calculating the economic costs of VDs. VDs affect workplace productivity and have associated absenteeism, medical, and economic costs. Increased awareness and education on the risk factors for VD development can assist with prevention, early diagnosis, and treatment. Accommodations and barriers are discussed.
CONCLUSION: There is emerging literature on VDs in the workplace. A multitude of VDs exist with varying pathologies, associated barriers, and implications for functioning within the workplace. Otolaryngologists play a unique role in diagnosing voice disorders and defining and facilitating workplace accommodations.
Pre- and Post- exercise training effects. Part of the participants were randomly assigned to underwent additional 24 sessions of supervised exercise training (SET) and the remaining participants follow the above instruction without additional supervised exercise training. After the 24 sessions of SET, they were then followed a 16-week of follow-up of their daily activities without additional exercise training.
A treatment with passive kinesitherapy, where the physiotherapist will perform the movements of flexion, abduction and rotation of the shoulder, without the patient's intervention; active kinesitherapy, where the patient will perform specifically prescribed movements, without weight, to improve the articular and muscular balance of the scapulohumeral complex and neurodynamics, where mobilisations of the accessory spinal nerve will be performed through therapeutic exercise and manual neurodynamic therapy. This treatment will be carried out once a week for two months in 30-minute sessions.
4-(6-oxo-2-(trifluoromethyl)-3,6-dichromeno[7,8-d]imidazole-8-yl)benzonitrile, also known as CF3CN, for use in the treatment of diseases or conditions associated with inflammation or autoimmunity, is provided. CF3CN is preferably administered with one or more pharmaceutically acceptable excipients. The diseases or conditions associated with inflammation or autoimmunity are as herein defined. The neuroprotective effect of CF3CN on damage induced by LPS on culture of mesencephalic neurons is exemplified. CF3CN may be administered as a single or multiple daily doses wherein the dose comprises at least 0.001mg of CF3CN. CF3CN may be administered with one or more additional drug products.
Fluoride ion concentrations are influenced by the duration of anesthesia, the concentration of sevoflurane administered, and the composition of the anesthetic gas mixture. In studies where anesthesia was maintained purely with sevoflurane for periods ranging from 1 to 6 hours, peak fluoride concentrations ranged between 12 M and 90 M. As shown in Figure 6, peak concentrations occur within 2 hours of the end of anesthesia and are less than 25 M (475 ng/mL) for the majority of the population after 10 hours. The half-life is in the range of 15-23 hours.

It has been reported that following administration of methoxyflurane, serum inorganic fluoride concentrations > 50 M were correlated with the development of vasopressin-resistant, polyuric, renal failure. In clinical studies with sevoflurane, there were no reports of toxicity associated with elevated fluoride ion levels.

Figure 6. Fluoride Ion Concentrations Following Administration of Sevoflurane (mean MAC = 1.27, mean duration = 2.06 hr) Mean Fluoride Ion Concentrations (n = 48)

Fluoride Concentrations After Repeat Exposure and in Special Populations

Fluoride concentrations have been measured after single, extended, and repeat exposure to sevoflurane in normal surgical and special patient populations, and pharmacokinetic parameters were determined.

Compared with healthy individuals, the fluoride ion half-life was prolonged in patients with renal impairment, but not in the elderly. A study in 8 patients with hepatic impairment suggests a slight prolongation of the half-life. The mean half-life in patients with renal impairment averaged approximately 33 hours (range 21-61 hours) as compared to a mean of approximately 21 hours (range 10-48 hours) in normal healthy individuals. The mean half-life in the elderly (greater than 65 years) approximated 24 hours (range 18-72 hours). The mean half-life in individuals with hepatic impairment was 23 hours (range 16-47 hours). Mean maximal fluoride values (C max) determined in individual studies of special populations are displayed below.
Epistaxis and Nasal Ulceration: In clinical trials of 2 to 26 weeks in duration, epistaxis was observed more frequently in patients treated with ZETONNA than those who received placebo. In the 26-week open-label extension of the perennial allergic rhinitis trial, nasal ulceration was identified in 4 of 824 patients administered ZETONNA (148 mcg) [see Adverse Reactions (6)].

The occurrence of local nasal adverse events was further evaluated in a separate, postmarketing 26-week randomized, open-label, active-controlled nasal and ocular safety trial conducted in patients with perennial allergic rhinitis. In this study epistaxis was observed in 6% of patients treated with ZETONNA and nasal ulceration was identified in 3 of 367 patients administered ZETONNA [see Adverse Reactions (6)].

Nasal Septal Perforation: Nasal septal perforation has been reported in patients following the nasal application of ZETONNA. Three short-term placebo-controlled trials (2 weeks) and one long-term (26 weeks with placebo control and 26 weeks open-label extension without placebo control) trial were conducted in patients with seasonal and perennial allergic rhinitis. Nasal septal perforations were reported in 2 patients out of 2335 patients treated with ZETONNA compared with none of 892 patients treated with placebo. No nasal septal perforations were reported in 367 patients treated with ZETONNA in a postmarketing 26-week, open-label, active-controlled trial in patients with perennial allergic rhinitis [see Adverse Reactions (6)].

Before starting ZETONNA conduct a nasal examination to ensure that patients are free of nasal disease other than allergic rhinitis. Periodically monitor patients with nasal examinations during treatment for adverse effects in the nasal cavity. If an adverse reaction (e.g. erosion, ulceration, perforation) is noted, discontinue ZETONNA. Avoid spraying ZETONNA directly onto the nasal septum.

Candida Infection: Localized infections of the nose or pharynx with Candida albicans has occurred from the use of ciclesonide. If such an infection occurs with ZETONNA, treat it with appropriate local therapy and discontinue ZETONNA. 

Impaired Wound Healing: Because of the inhibitory effect of corticosteroids on wound healing, patients who have experienced recent nasal septal ulcers, nasal surgery, or nasal trauma should not use ZETONNA until healing has occurred.
The invention provides a novel chitosan application containing a chitosan mixture. The chitosan application is composed of a back lining layer, a cushion layer, release paper and the chitosan mixture. The chitosan mixture is distributed into the cushion layer. The cushion layer is located in the middle section of the back lining layer. The release paper is stuck to the two ends of the back lining layer. The chitosan mixture is composed of high-molecular-weight chitosan and low-molecular-weight chitosan in a mixed mode. The high-molecular-weight chitosan and the low-molecular-weight chitosan are dissolved into a weak acid solution to prepare chitosan mixed liquor, and then a wetting method or a spray painting method is adopted for uniformly distributing the mixed liquor to the surface and the interior of the cushion layer. The application has a function of a common application and has particular pharmacological action of chitosan, and functions of resisting bacteria, preserving moisture, relieving pain, promoting wound healing, reducing scar formation and the like of the application are newly increased or reinforced. The application is easy to manufacture, low in cost and free from irritation to the human body, has no obvious toxicity and can be widely applied to treatment of wounds.
Group bupivacaine - Dexametomedine (D) received 0.5 mL/kg bupivacaine 0.25% with dexmedetomidine 1 µg/kg. diluted with isotonic saline (total volume 15ml).
The study is designed to meet regulatory requirement outside the US. The dosing regimen and assessments timepoints were dictated by IR GGE and do not match approved Mucinex labeling. Participants were instructed to take 2 Mucinex 600 mg tablets and 1 placebo tablet matching the 200 mg IR guaifenesin tablet by mouth, every 12 hours for 7 days. To ensure complete blinding, on Hours 6 and 18, this treatment group took 2 matching Mucinex placebo tablets combined with 1 IR guaifenesin placebo tablet.
BACKGROUND & AIMS: Addition of sialic acids (sialylation) to glycoconjugates is a common capping step of glycosylation. Our study aims to determine the roles of the overall sialylation in intestinal mucosal homeostasis.
METHODS: Mice with constitutive deletion of intestinal epithelial sialylation (IEC Slc35a1-/- mice) and mice with inducible deletion of sialylation in intestinal epithelium (TM-IEC Slc35a1-/- mice) were generated, which were used to determine the roles of overall sialylation in intestinal mucosal homeostasis by ex vivo and mutiomics studies.
RESULTS: IEC Slc35a1-/- mice developed mild spontaneous microbiota-dependent colitis. Additionally, 30% of IEC Slc35a1-/- mice had spontaneous tumors in the rectum greater than the age of 12 months. TM-IEC Slc35a1-/- mice were highly susceptible to acute inflammation induced by 1% dextran sulfate sodium versus control animals. Loss of total sialylation was associated with reduced mucus thickness on fecal sections and within colon tissues. TM-IEC Slc35a1-/- mice showed altered microbiota with an increase in Clostridium disporicum, which is associated a global reduction in the abundance of at least 10 unique taxa; however, metabolomic analysis did not show any significant differences in short-chain fatty acid levels. Treatment with 5-fluorouracil led to more severe small intestine mucositis in the IEC Slc35a1-/- mice versus wild-type littermates, which was associated with reduced Lgr5+ cell representation in small intestinal crypts in IEC Slc35a1-/-;Lgr5-GFP mice.
CONCLUSIONS: Loss of overall sialylation impairs mucus stability and the stem cell niche leading to microbiota-dependent spontaneous colitis and tumorigenesis.
AIM: To investigate the clinical and radiological features to predict adhesion between vestibular schwannoma (VS) and brain tissue which is a critical risk factor for postoperative infarction and residual tumour.
MATERIAL AND METHODS: One hundred and seven consecutive VS surgeries were analysed. After excluding cases without contrast-enhanced (CE) computed tomography (CT), Koos grades 1 and 2, and cases with incomplete clinical data, 44 patients were finally included in the study. Enhancement of the tumour capsule on the brainstem side on CE-CT was defined as the CE-CT rim sign, which was analysed along with clinical characteristics, including tumour adhesion and postoperative complications.
RESULTS: Eight patients exhibited CE-CT rim signs; 17 had tumour adhesions. Four patients had postoperative infarction at the ipsilateral middle cerebellar peduncle; 18 exhibited postoperative infarction and/or residual tumour at the middle cerebellar peduncle. The CE-CT rim sign significantly correlated with tumour adhesion, postoperative infarction, and postoperative infarction and/or residual tumour in the cerebellar peduncle. Univariate regression analysis revealed that the CE-CT rim sign significantly correlated with tumour adhesion (odds ratio [OR] 6.81, 95% confidence interval [CI] 1.18-39.25, p=0.032) and postoperative infarction and/or residual tumour at the cerebellar peduncle (OR 6.00, 95% CI 1.04-34.31, p=0.044).
CONCLUSION: The CE-CT rim sign was identified in 18.2% of patients with VS and significantly correlated with tumour adhesion and postoperative complications, such as postoperative infarction and residual tumour. This study highlights the importance of the preoperative CE-CT rim sign in VS, which is predictive of tumour adhesion and postoperative complications.
Many studies have suggested that caesarean-delivered children are at higher risks of developing metabolic and allergic diseases like obesity and asthma, possibly because newborns born by caesarean section were lack of exposure to maternal vaginal flora. It is needed to explore a simple, convenient, and safe intervention strategy to reduce caesarean-related risks. In a recent non-randomized study, the authors found that exposure of caesarean-delivered newborns to maternal vaginal fluid at birth (i.e., vaginal seeding) could partially restore the microbiota of them at 30 days after births, but the long-term health consequences of restoring the microbiota of caesarean-delivered infants remain unclear.

In this randomized study, the investigators aim to examine whether the changes in newborns' microbiota will persist to 24 month of age, and whether vaginal seeding will have any effects on body mass index and allergy risk from birth to 24 months of age. the investigators will enroll a total of 106 pregnant women, and the participants' infants will be followed up at 0 (before hospital discharge), 6, 12, 18 and 24 months. At each follow-up visit, a questionnaire survey including information on feeding, medication, and allergic status will be conducted, infants' height and weight will be measured, and feces will be collected. At 18-month-old visit, infants' venous blood will be also collected for the assay of multiallergen. The primary outcomes were body mass index and allergy risk index. The secondary outcomes included the microbiota profile, allergic symptoms and diseases, overweight/obesity, and adverse effects.
PURPOSE:To provide the titled composition resistant to water, having excellent adhesivity to the skin, and giving a coating film having high releasing rate of the drug contained therein, by compounding shellac to a solvent composed mainly of a lower alcohol. CONSTITUTION:The objective composition for epidermis can be prepared by compounding shellac to a solvent composed mainly of a lower alcohol. Shellac has been examined as a coating material of tablet or a raw material of a slow- releasing preparation. When shellac is used in a film-forming composition for epidermis, a composition having improved water-resistance, action of drug-retaining matrix, high safety and excellent adhesivity to the skin, and moisturizing effect to the skin can be obtained. The composition also has high activity to release the contained drugs such as disinfectant (e.g. benzalkonium chloride), anti-inflammatory and analgesic (e.g. salicylic acid), etc. The amounts of shellac, drug and the lower alcohol are preferably 1-50%, 0.01-30% and 95-40%, respectively.
1,186,480. Dentures. CESKOSLOVENSKA AKADEMIE VED. 2 Aug., 1968 [16 Aug., 1967], No..37012/68. Heading A5R. [Also in Division C3] Artificial dentures are provided with a. soft hydrogel layer by polymerising as a layer onto the surface of the hard polymer of which the denture is composed, using a polymerisation initiator, a mixture of a non-crosslinked, soluble glycol mono-acrylate or -methacrylate polymer or copolymer, monomeric glycol mono-acrylate or -methacrylate containing 0.05-2.00% by weight (based on total monomer) of the corresponding diester, and a water soluble, substantially anhydrous solvent capable of dissolving said non-crosslinked polymer as well as the hard polymer of the denture, the solvent being used in an amount of 5-50% by weight (based on the total mixture); and thereafter completely removing said solvent by washing and replacing it by water. The denture may be composed of methyl methacrylate, ethyl methacrylate or benzyl methacrylate polymer. Polymerisation initiators specified are methyl ethyl ketone hydroperoxide, diisopropyl percarbonate, benzoyl peroxide and persulphates; these may be used in conjunction with a reducing agent such as 2-diethylaminoethyl acetate, dimethylaniline or p-toluene sulphinic acid. Preferred watersoluble solvents are ethylene glycol mono-acetate and glycerol diacetates; other suitable solvents include mono-lower alkyl ethers of ethylene glycol or polyethylene glycol, dimethylformamide, monomethylformamide, formamide and glacial acetic acid. The glycol component of the (meth) acrylate may be ethylene glycol, diethylene glycol, triethylene glycol, propylene glycol or 1,4-butylene glycol. In one Example, a red pigment and finely divided silica are included in the hydrogel layer.
Technology for predicting potential disease diagnoses of patients is disclosed. In an example, data associated with a patient is accessed. The data is divided into one or more queries. Each of the one or more queries is associated with one or more keywords. For each of the one or more queries, a plurality of literatures based on the one or more keywords is generated. A plurality of terms extracted from each of the plurality of literatures for each of the one or more queries is merged into a combined list of terms. One or more potential diagnoses are provided based on the combined list of terms.
PURPOSE: To provide a lipid polymer compsn. used for bleaching of the discolored teeth or prevention of tooth discoloration. CONSTITUTION: This liquid polymer compsn. contains a water-soluble and low- viscosity cellulose polymer and bleaching agent and is prepd. by adding a stabilizing agent to disodium calcium ethylenediaminetetraacetate, etc. The compsn. is useful for removal of the dental plaque or for treatment of periodontal diseases, such as gingivitis in addition bleaching of the teeth and the prevention of the tooth discoloration.
DX-88 (ecallantide) Patients were treated with DX-88 (ecallantide) when they experienced an HAE attack. 30 mg dose of ecallantide given via 3 SC injections; a second 30 mg dose can be administered if needed. Patients were to be assessed until 4 hrs post-dose. Patients were asked to return for 3 follow-up visits: 7 days, 28 days and 90 days post-dose.
Children will receive 2 testing (talking) exposures and 4 listening exposures for a total of 6 exposures to each word. This is a listening and talking condition with mostly listening.
AIM: Atrial fibrillation (AF), the most common arrhythmia, is characterized by atrial electrical and structural remodeling. Previous studies have found that sodium-glucose cotransporter 2 inhibitor (SGLT2i) can protect myocardium in a glucose independent mechanism. But the role of SGLT2i in regulating AF remains largely unknown. This study, we aimed to investigate the effect of Dapagliflozin (DAPA) in reducing AF susceptibility via inhibiting electrical and structural remodeling.
METHOD: The mouse model was established by Angiotensin II (2000 ng/kg/min) infusion for 3 weeks, and an in vitro model was generated by stimulating HL-1 and primary mouse fibroblast with Ang II (1 μM) for 24 h. Programmed electrical stimulation, ECG and whole-cell patch clamp were used to detect DAPA effect on atrial electrical remodeling induced by Ang II. To observe DAPA effect on atrial structural remodeling induced by Ang II, we used echocardiographic, H&E and Masson staining to evaluate atrial dilation. To further explore the protective mechanism of DAPA, we adopt in silico molecular docking approaches to investigate the binding affinity of Ang II and CaMKII at Met-281 site. Western blot was to detect expression level of CaMKII, ox-CaMKII, Nav1.5, Kv4.3, Kv4.2, Kchip2, Kir2.1 and Cx40.
RESULTS: Ang II induced AF, atrial dilatation and fibrosis, led to atrial electrical and structural remodeling. However, these effects were markedly abrogated by DAPA treatment, a specific SGLT2i. Our observation of atrial electrical activity in mice revealed that DAPA could rescue the prolonged action potential duration (APD) and the abnormal currents of IK1, Ito and INaL triggered by Ang II infusion. DAPA could reduce the binding affinity of Ang II and CaMKII at Met-281 site, which indicated that DAPA may directly alleviate the activation of CaMKII caused by Ang II. DAPA could reduce the upregulation of ox-CaMKII caused by Ang II infusion in atrial tissues. Moreover, DAPA also ameliorated the aberrant expression levels of electrical activity related proteins (Nav1.5, Kv4.3, Kv4.2, Kchip2, Kir2.1 and Cx40) and fibrosis related signal pathways (TGF-β1, p-smad/smad) caused by Ang II. Furthermore, we confirmed that DAPA, as well as other SGLT2i (EMPA, CANA), could reverse these abnormalities caused by Ang II incubation in HL-1 cells and primary mouse fibroblasts, respectively.
CONCLUSION: Overall, our study identifies DAPA, a widely used SGLT2i, contributes to inhibiting Ang II-induced ox-CaMKII upregulation and electrical and structural remodeling to reduce AF susceptibility, suggesting that DAPA may be a potential therapy of treating AF.